Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/16867
Title: | The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: A comparative study | Authors: | Hompes, D. D'Hoore, A. Wolthuis, A. FIEUWS, Steffen Mirck, B. Bruin, S. Verwaal, V. |
Issue Date: | 2014 | Source: | JOURNAL OF SURGICAL ONCOLOGY, 109 (6), p. 527-532 | Abstract: | Background Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC). Methods Patient cohorts from two different HIPEC-centers underwent cytoreductive surgery and HIPEC with Oxaliplatin (39 patients) and MMC (56 patients), respectively. They were compared for toxicity and survival data. The extent of PC was assessed using the Dutch 7-region count. Results The median 7-region count was 4 [range 0–7] for Oxaliplatin-patients versus 2.5 [range 1–6] for MMC-patients (P = 0.004). Median intra-operative blood loss was 650 ml [0–6,000 ml] in Oxaliplatin-patients versus 1,230 ml [range 0–5,300 ml] in MMC-patients (P < 0.001). Only MMC-patients developed neutropenia/leucopenia (26.8%, P < 0.001). After statistical correction for the extent of PC, the overall postoperative complication rate was significantly higher in MMC-patients (OR = 2.68 (95% CI: 1.04–6.91), P = 0.04), with a comparable intra-abdominal complication (IAC) rate (OR = 0.78 (95% CI: 0.30–2.03), P = 0.61), but a tendency towards more extra-abdominal complications (EAC) in MMC-patients (OR = 2.23 (95% CI: 0.91–5.43), P = 0.079). Median follow-up was significantly shorter for Oxaliplatin-patients (2.8 years) than for MMC-patients (5.1 years). Median RFS was 12.2 months [IQR: 7.2-undefined] in the Oxaliplatin-group and 13.8 months [IQR: 7.0–25.8] in the MMC-group (P = 0.87). Median OS is 37.1 months [IQR: 22.4–52.8] for Oxaliplatin-patients and 26.5 months [IQR: 16.9–64.8] for MMC-patients (P = 0.45). Logistic regression analysis (corrected for extent of PC) shows RFS (HR = 1.24 (95% CI: 0.75–2.05), P = 0.39) and OS (HR = 1.37 (95% CI: 0.74–2.54), P = 0.32) are not significantly different. Conclusions No clear benefit in RFS and OS for HIPEC with Oxaliplatin or MMC could be demonstrated in patients with PC from CRC. J. Surg. Oncol. 2014 109:527–532. © 2013 Wiley Periodicals, Inc. | Notes: | Hompes, D (reprint author),Univ Hosp Gasthuisberg, Herestr 49, B-3000 Louvain, Belgium daphne.hompes@uzleuven.be | Keywords: | colorectal cancer; peritoneal carcinomatosis; HIPEC; Oxaliplatin; Mitomycin C | Document URI: | http://hdl.handle.net/1942/16867 | ISSN: | 0022-4790 | e-ISSN: | 1096-9098 | DOI: | 10.1002/jso.23546 | ISI #: | 000334183600005 | Rights: | © 2013 Wiley Periodicals, Inc. | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2015 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hompes 1.pdf Restricted Access | Published version | 258.51 kB | Adobe PDF | View/Open Request a copy |
SCOPUSTM
Citations
58
checked on Sep 7, 2020
WEB OF SCIENCETM
Citations
86
checked on Aug 19, 2024
Page view(s)
112
checked on Sep 7, 2022
Download(s)
94
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.